• On sale!
search

Vicks sinex aloe nasal spray 0.05 decongestant

  • Procter & Gamble S.r.l.
  • 023198029

Vicks sinex Aloe, decongestant nasal nebulizer enriched with aloe vera. Thanks to its formulation, it does not dry out the nasal mucosa.

We recommend 1 or 2 sprays 2 times a day.

Carefully read the package insert inside.


info_outline View product sheet
Final Price €12.17

Volume discounts

Quantity Unit discount You Save
2 10% €2.43
5 20% €12.17
10 35% €42.60
Quantity
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Other products Others products at unbeatable price

Procter & Gamble S.r.l.

Discover all products

VICKS SINEX ALOE 0.05% SOLUTION TO BE NEBULIZED

Therapeutic indications

Decongestant of the nasal mucosa, especially in case of colds.

Dosage and method of use

Adults and children over 12 years: 1-2 sprays per nostril every 8 - 12 hours, unless otherwise indicated by the doctor. Hold the bottle in a vertical position, insert its end into the nostril and press the nebulizer quickly and firmly. After application, inhale deeply with your mouth closed.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1, prostatic hypertrophy, severe heart disease and arterial hypertension. Glaucoma, hyperthyroidism. Do not administer during and in the two weeks following therapy with antidepressant drugs (MAOI). Inflammation or lesions of the oral mucosa or the skin around the nostrils. The drug is contraindicated in children under 12 years of age.

Side effects

If accidentally ingested or if used for a long period in excessive doses, the product can cause toxic phenomena. The product can locally cause sensitization phenomena and rebound congestion of the mucous membranes. In general, no serious side effects were observed. Due to rapid absorption of oxymetazoline through inflamed mucous membranes, side effects may occur divided into the following frequencies: very common (≥1/10); common (≥1/100, 1/10000); not known (frequency cannot be estimated from the available data). Rare: Eye pathologies: eye irritation, discomfort or redness.Respiratory, thoracic and mediastinal disorders: discomfort or irritation of the nose, mouth or throat, sneezing. Very rare: Cardiac diseases: tachycardia, palpitations, increased blood pressure, reflex bradycardia.Central nervous system disorders: insomnia, nervousness, tremor, anxiety, agitation, irritability and headache.Gastrointestinal disorders: nausea.Renal and urinary disorders: urination disorders.Reporting of suspected adverse reactionsReporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

Use with caution in the first months of pregnancy and, due to the risk of urinary retention, in the elderly. Also use with caution in patients with angina and diabetes. If symptoms persist, a clinical reassessment must be considered; in any case, treatment must not be continued for more than 4 consecutive days to avoid a rebound effect and rhinitis phenomena induced by the drug. Carefully follow the recommended doses. Accidental ingestion may cause severe sedation. It should not be used orally. Avoid contact of the liquid with the eyes. Prolonged use of vasoconstrictors can alter the normal function of the mucosa of the nose and paranasal sinuses, also inducing addiction to the drug. Repeating applications for long periods can be harmful. The use, especially if prolonged, of topical products can give rise to sensitization phenomena; in this case it is necessary to interrupt the treatment and institute suitable therapy.Important information about some excipientsVicks Sinex Aloe 0.05% nebulizer solution contains benzalkonium chloride may cause bronchospasm. This medicine contains 0.01 mg of benzalkonium chloride per dose (1 spray) which is equivalent to 0.2 mg/ml. Benzalkonium chloride can cause irritation and swelling inside the nose, especially if used for long periods. Vicks Sinex Aloe 0.05% spray solution contains benzyl alcohol. This medicine contains 0.1 mg of benzyl alcohol per dose (1 spray), equivalent to 2 mg/ml. Benzyl alcohol can cause allergic reactions. Benzyl alcohol may cause mild local irritation

Pregnancy and breastfeeding

There are no studies on the use of the product during pregnancy and breastfeeding. Use with caution in the first months of pregnancy. Administration should only be considered if the expected benefit to the mother outweighs the risk to the baby.

Expiration and conservation

This medicine does not require any special storage conditions.

Interactions with other drugs

There is the possibility of interaction between sympathomimetic amines such as oxymetazoline with anti-MAO drugs and therefore their use is not recommended during or in the two weeks following treatment with anti-MAO drugs (see section 4.3). Oxymetazoline could reduce the effectiveness of beta-blocking drugs, methyl dopa or other antihypertensive drugs. Hypertension and arrhythmias may occur when tricyclic antidepressants are administered with sympathomimetic drugs such as oxymetazoline. Increased cardiovascular toxicity may occur when sympathomimetic drugs are administered concomitantly with antiparchinsonian drugs such as bromocriptines.

Overdose

SymptomsSymptoms due to moderate or acute overdose may include mydriasis, nausea, cyanosis, fever, tachycardia, cardiac arrhythmias, hypertension, dyspnea, cardiac arrest, photophobia, headache, intense chest tightness and, in children, severe Central Nervous System depression with symptoms such as decreased body temperature, bradycardia, hypotension, apnea and loss of consciousness which require the adoption of appropriate emergency measures.TreatmentTreatment should be symptomatic. In more serious cases, intubation and artificial respiration are required.

Active principles

- Active ingredient: oxymetazoline hydrochloride 0.0500% w/v. 1 ml of product contains 0.5 mg of oxymetazoline hydrochloride. 1 spray (50 microlitres) contains approximately 25 micrograms of oxymetazoline hydrochloride. - Excipients with known effects: benzalkonium chloride, benzyl alcohol For the complete list of excipients, see section 6.1.

Excipients

Levomenthol, sodium citrate, anhydrous citric acid, benzalkonium chloride solution, disodium edetate, eucalyptol (cineole), non-crystallizable liquid sorbitol, aloe vera, acesulfame potassium, Lcarvone, polysorbate 80, benzyl alcohol and purified water.

023198029

Data sheet

Packaging
nebulizer 15 ml
Product Type
HUMAN DRUG
ATC code
R01AA05
ATC description
Oximetazoline
Therapeutic Group
Decongestants
Active principle
oximetazoline hydrochloride (FU)
Class
C.
Pharmaceutical form
spray
Type of Administration
nasal
Container
spray / can
Quantity
1 spray
Capacity
15 milliliters
Quantity of the Active Ingredient
, 5MG
Recipe required
OTC - self-medication medicine
chat Comments (0)
Fast Order